Sarah Duellman

Promega: Promega Corporation is a worldwide leader in applying biochemistry and molecular biology to developing innovative, high-value products for the life sciences. Wisconsin-based manufacturer of enzymes and other biotechnology and molecular biology products with a portfolio covering genomics, protein analysis, expression, cellular analysis, drug discovery, and genetic identity. Promega exists on an evolutionary frontier where the values of science, business, and human well-being intersect. Acknowledging these interdependencies, Promega cultivates its environment to allow employees to flourish, develop deep and enduring relationships with all constituencies and create intelligent life-science solutions.‍

Bio Highlights: Sarah Duellman, Ph.D., leads global biotech strategy at Promega Corporation, where she helps shape how the company supports emerging and established biotech organizations worldwide. A research scientist turned technical and commercial advisor, she identifies emerging trends in drug discovery and aligns Promega’s technology portfolio with the evolving needs of the biotech ecosystem.

In her role, Sarah develops and executes global commercialization strategies and leads Promega’s engagement with biotech incubators and early-stage companies, building partnerships that support innovation and growth. She serves on the advisory board of Forward Biolabs and works closely with incubators and accelerators globally.

Sarah previously spent several years in R&D at Promega developing cell health technologies before transitioning into sales and market-facing roles supporting drug discovery researchers. She holds a Ph.D. in Genetics from the University of Wisconsin–Madison, completed postdoctoral training at SRI International, and earned a B.S. from Illinois State University.